Drugs for Inherited Retinal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 20)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ranibizumab |
Approved |
Phase 2 |
|
347396-82-1 |
459903 |
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
2 |
|
Acetazolamide |
Approved, Vet_approved |
Phase 2 |
|
59-66-5 |
1986 |
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2-acetylamino-1,3,4-Thiadiazole-5-sulphonamide
2h4n
3czv
4-Diamox
5661-25-6
59-66-5
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
5-acetamido-1,3,4-THIADIAZOLE-2-sulfonamide
5-acetamido-1,3,4-THIADIAZOLE-2-sulphonamide
5-acetylamino-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulphonamide
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
acetazolamide
Acetazolamide
Acétazolamide
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide [INN:BAN:JAN]
Acetazolamide apotex brand
Acetazolamide Apotex Brand
Acetazolamide chiesi brand
Acetazolamide Chiesi Brand
Acetazolamide dioptic brand
Acetazolamide Dioptic Brand
Acetazolamide grin brand
Acetazolamide Grin Brand
Acetazolamide icn brand
Acetazolamide ICN Brand
Acetazolamide jumer brand
Acetazolamide Jumer Brand
Acetazolamide llorens brand
Acetazolamide Llorens Brand
Acetazolamide medphano brand
Acetazolamide Medphano Brand
Acetazolamide novopharm brand
Acetazolamide Novopharm Brand
Acetazolamide orion brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide sodium, (sterile)
Acetazolamide Sodium, (Sterile)
Acetazolamide wassermann brand
Acetazolamide Wassermann Brand
Acetazolamide, monosodium salt
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
AI3-52458
Ak zol
Ak Zol
AKOS000715163
Ak-zol
AkZol
Ak-Zol
apo Acetazolamide
Apo Acetazolamide
apo-Acetazolamide
ApoAcetazolamide
Apo-Acetazolamide
Apotex brand OF acetazolamide
Apotex Brand of Acetazolamide
Atenezol
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
Carbonic anhydrase inhibitor 6063
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
Chiesi brand OF acetazolamide
Chiesi Brand of Acetazolamide
Ciba vision brand OF acetazolamide
Ciba Vision Brand of Acetazolamide
CID1986
Cidamex
CPD000058394
CPD0-1626
Cyanamid brand OF acetazolamide preparation
D000086
D00218
Dazamide
DB00819
Defiltran
Défiltran
Dehydratin
Diacarb
Diakarb
Diamox
|
Diamox (TN)
Diamox Sequels
Didoc
Diluran
Dioptic brand OF acetazolamide
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-holzinger
Diureticum-Holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
Edemox
EINECS 200-440-5
EU-0100039
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin brand OF acetazolamide
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma zolamide
Huma Zolamide
Huma-zolamide
HumaZolamide
Huma-Zolamide
I09-0425
ICN brand OF acetazolamide
ICN Brand of Acetazolamide
IDI1_000017
Jumer brand OF acetazolamide
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
Lederle brand OF acetazolamide preparation
Llorens brand OF acetazolamide
Llorens Brand of Acetazolamide
Lopac0_000039
Lopac-A-6011
LS-10227
medphano Brand OF acetazolamide
Medphano Brand of Acetazolamide
MLS000028435
MLS001148438
MolPort-001-783-578
Monosodium salt acetazolamide
Monosodium Salt Acetazolamide
N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
N-[5-(Aminosulphonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulphonyl)-1,3,5-thiadiazol-2-yl]acetamide
Natrionex
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
Nephramid
Nephramide
NINDS_000017
Novopharm brand OF acetazolamide
Novopharm Brand of Acetazolamide
NSC 145177
NSC145177
Orion brand OF acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick_4
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
SAM002554883
SBB056640
Sk-Acetazolamide
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
Spectrum_000018
SPECTRUM1500102
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Storz brand OF acetazolamide preparation
Storz Brand of Acetazolamide Preparation
Storzolamide
Théraplix brand OF acetazolamide preparation
UNII-O3FX965V0I
Vetamox
Wassermann brand OF acetazolamide
Wassermann Brand of Acetazolamide
Whelehan brand OF acetazolamide preparation
WLN: T5NN DSJ CSZW EMV1
Wyeth brand OF acetazolamide preparation
Wyeth Brand of Acetazolamide Preparation
|
|
3 |
|
Brinzolamide |
Approved |
Phase 2 |
|
138890-62-7 |
68844 |
Synonyms:
(+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
138890-62-7
2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
3znc
AB00513824
AC1L2AKA
AC1Q6UVB
AC-5277
AKOS005145708
AL 4862
AL04862
AL-4862
Alcon brand of brinzolamide
Alcon brand OF brinzolamide
Allphar brand of brinzolamide
Allphar brand OF brinzolamide
Azopt
Azopt (TN)
BIDD:GT0039
Birnzolamide
BPBio1_000539
BRD-K74913225-001-03-3
Brinzolamida
|
Brinzolamide
Brinzolamide (BRZ)
Brinzolamide (JAN/USP/INN)
Brinzolamide [USAN]
BSPBio_000489
BZ1
C07760
C111827
C12H21N3O5S3
CHEBI:3176
CHEMBL220491
CID68844
D00652
DB01194
FT-0082471
HMS1569I11
I09-0605
LS-173036
MLS002153787
MolPort-005-940-291
Prestwick0_000365
Prestwick1_000365
Prestwick2_000365
Prestwick3_000365
SMR001233169
SPBio_002410
UNII-9451Z89515
|
|
4 |
|
Minocycline |
Approved, Investigational |
Phase 2 |
|
10118-90-8 |
5281021 |
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-dimethylamino-6-Demethyl-6-deoxytetracycline
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
Bio-0062
Borymycin
BRN 3077644
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
Lactoferrin B & Minocycline
|
Lactoferrin H & Minocycline
LMPK07000002
LS-93850
MINO
Minociclina
Minociclina [INN-Spanish]
minociclinum
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
minocycline
Minocycline
Minocycline (USAN/INN)
Minocycline [USAN:BAN:INN]
Minocycline HCl
Minocycline Monohydrochloride
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
MIY
NCGC00178854-01
nchembio.559-comp1
Novo-Minocycline
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
|
|
5 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
6 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 2 |
|
|
|
7 |
|
Mitogens |
|
Phase 1, Phase 2 |
|
|
|
8 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
9 |
|
Ophthalmic Solutions |
|
Phase 1, Phase 2 |
|
|
|
10 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
11 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
12 |
|
Anesthetics |
|
Phase 2 |
|
|
|
13 |
|
Antioxidants |
|
Phase 2 |
|
|
|
14 |
|
Protective Agents |
|
Phase 2 |
|
|
|
15 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
16 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
17 |
|
Citrate |
|
|
|
|
|
18 |
|
Gastrins |
|
|
|
|
|
19 |
|
Insulin, Globin Zinc |
|
|
|
|
|
20 |
|
insulin |
|
|
|
|
|
Interventional clinical trials:
(show all 31)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] |
Active, not recruiting |
NCT00999609 |
Phase 3 |
|
2 |
A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations |
Unknown status |
NCT01278277 |
Phase 1, Phase 2 |
|
3 |
An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA) |
Completed |
NCT02781480 |
Phase 1, Phase 2 |
|
4 |
Efficacy and Safety of Intravitreal Ranibizumab (Lucentis®) Injection in the Treatment of Non-leaking Macular Cysts in Patients With Retinal Dystrophy. |
Completed |
NCT03763227 |
Phase 2 |
Intravitreal ranibizumab (IVR) injection;Carbonic Anhydrase Inhibitor (CAI) therapy |
5 |
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (AAV2/2-hRPE65p-hRPE65) for Gene Therapy of Severe Early-onset Retinal Degeneration |
Completed |
NCT00643747 |
Phase 1, Phase 2 |
|
6 |
Prospective Monocentric Open Label Non Randomized Uncontrolled Phase I/II Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65 |
Completed |
NCT01496040 |
Phase 1, Phase 2 |
rAAV2/4.hRPE65 |
7 |
A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP. |
Completed |
NCT02110225 |
Phase 1, Phase 2 |
rhNGF 60 µg/ml eye drops solution;rhNGF 180 µg/ml eye drops solution;Placebo |
8 |
The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial |
Recruiting |
NCT04068207 |
Phase 2 |
Minocycline |
9 |
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression |
Recruiting |
NCT03328130 |
Phase 1, Phase 2 |
|
10 |
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) |
Recruiting |
NCT01773278 |
Phase 2 |
Antioxidants;Cholesterol |
11 |
Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy (Title in France: Compensation of Vision With the Intelligent Retinal Implant System (IRIS V1) in Patients With Retinal Dystrophy) |
Completed |
NCT01864486 |
|
|
12 |
Genetical, Multi-center, Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy |
Completed |
NCT00422721 |
|
|
13 |
Optical Head-Mounted Display Technology for Low Vision Rehabilitation |
Completed |
NCT02983305 |
|
|
14 |
Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy |
Completed |
NCT02670980 |
|
|
15 |
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families: Establishment of Genotype-phenotype Correlations and Updating the Clinical Definition of This Retinal Dystrophy |
Completed |
NCT02970266 |
|
|
16 |
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa |
Completed |
NCT04238858 |
|
|
17 |
One-Year Natural History Study of Retinitis Pigmentosa Due to RHO, PDE6A or PDE6B Mutations |
Recruiting |
NCT04285398 |
|
|
18 |
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2) |
Recruiting |
NCT02946879 |
|
|
19 |
Establishment of the National Registry for Inherited Retinal Dystrophy in Iran |
Recruiting |
NCT04131400 |
|
|
20 |
Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinal Dystrophy Patients |
Recruiting |
NCT02014389 |
|
|
21 |
Study on the Effects of Mutations Under Inherited Retinal Disease in Korean |
Recruiting |
NCT03613948 |
|
|
22 |
The Natural History of Mucolipidosis Type IV |
Recruiting |
NCT01067742 |
|
|
23 |
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) |
Recruiting |
NCT03349242 |
|
|
24 |
Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II |
Recruiting |
NCT03011541 |
|
|
25 |
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec |
Active, not recruiting |
NCT03597399 |
|
|
26 |
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection |
Active, not recruiting |
NCT03602820 |
|
|
27 |
Natural History of the Progression of Choroideremia Study |
Active, not recruiting |
NCT03359551 |
|
|
28 |
Bone Marrow Derived Stem Cell Ophthalmology Treatment Study |
Enrolling by invitation |
NCT01920867 |
|
|
29 |
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS |
Terminated |
NCT03561922 |
|
|
30 |
Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease |
Terminated |
NCT01676766 |
|
|
31 |
Bardet-Biedl Syndrome: Phenotype and Metabolic Characteristics |
Terminated |
NCT00078091 |
|
|
|